A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 61, Issue 10, Pages 1754-1760
Publisher
Wiley
Online
2014-06-30
DOI
10.1002/pbc.25117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
- (2014) Yuki Kagoya et al. JOURNAL OF CLINICAL INVESTIGATION
- Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF- B
- (2013) L. Bastian et al. CLINICAL CANCER RESEARCH
- Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors
- (2013) I. Tagoug et al. CLINICAL CANCER RESEARCH
- Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
- (2013) Gertjan J.L. Kaspers et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
- (2013) Lindsey N. Micel et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia
- (2013) D Koyama et al. LEUKEMIA
- Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group
- (2013) Todd M. Cooper et al. PEDIATRIC BLOOD & CANCER
- Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
- (2013) Sabrina Manni et al. PLoS One
- Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance
- (2012) Van Thanh Hoang et al. Biotechnology Journal
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
- (2012) U. Creutzig et al. BLOOD
- Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
- (2012) L. Barreyro et al. BLOOD
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
- (2012) Y. H. Messinger et al. BLOOD
- Gene Sets Identified with Oncogene Cooperativity Analysis Regulate In Vivo Growth and Survival of Leukemia Stem Cells
- (2012) John M. Ashton et al. Cell Stem Cell
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
- (2012) Eyal C. Attar et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
- (2012) Jodi A. Muscal et al. PEDIATRIC BLOOD & CANCER
- Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
- (2011) Marina Y. Konopleva et al. JOURNAL OF CLINICAL ONCOLOGY
- Stem cell gene expression programs influence clinical outcome in human leukemia
- (2011) Kolja Eppert et al. NATURE MEDICINE
- Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
- (2010) Andrew J. Gentles JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice
- (2010) Jean-Emmanuel Sarry et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
- (2010) Yoav Messinger et al. PEDIATRIC BLOOD & CANCER
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
- (2008) E. C. Attar et al. CLINICAL CANCER RESEARCH
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
- (2008) Elizabeth A. Raetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started